In this video, IMF Chairman Brian G.M. Durie moderates a discussion with Dr. Joseph Mikhael (IMF Chief Medical Officer) and Dr. Philippe Moreau (University of Nantes - Nantes, France) about new agents for multiple myeloma, such as CAR T-cell therapies, AMG 420 BiTE, and CELMoD (CC220).

This video is the fifth in a five-part series that focuses on making sense of multiple myeloma treatment based upon the newly obtained input from the American Society of Clinical Oncology (ASCO) and the International Myeloma Working Group 2019 Summit.

Download Slides (https://s3.us-west-1.wasabisys.com/imf-d8-prod/slides/Amsterdam_ConferenceSeries_IMWG19.pdf)

Topics Covered:

• Smoldering Myeloma (https://www.myeloma.org/node/2309)
• Frontline Therapy (https://www.myeloma.org/node/2310)
• Maintenance (https://www.myeloma.org/node/2311)
• Relapse Therapies (https://www.myeloma.org/node/2312)
• New Agents (https://www.myeloma.org/node/2313)

Thank you to our sponsors:
Takeda Oncology